Theravance Biopharma Inc (NASDAQ: TBPH). Extremely significant positive changes in investment behavior have recently occurred: its shorter term price trend turned up, the stock’s recent price rise disrupted its longer term downtrend, positive upside/downside volume developed, and the stock rose on very heavy volume.
In light of these very positive signals we are reviewing our current Overall Rating of F. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
TBPH’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to continue to be Value Creation neutral.
Theravance Biopharma has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Theravance Biopharma has a poor Power Rating of 28 and a poor Appreciation Score of 18, producing the Lowest Value Trend Rating.
Recent Price Action
Theravance Biopharma Inc (NASDAQ: TBPH) stock enjoyed a very large increase of 5.3% on 11/8/23. The shares closed at $10.25. The stock has risen 8.6% during the last week and has performed in line with the market over the last nine months.
Be the first to comment